PDG26 COST-EFFECTIVENESS OF RANIBIZUMAB VERSUS VERTEPORFIN PHOTODYNAMIC THERAPY IN THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGICAL MYOPIA: FROM CHINESE SOCIETAL PERSPECTIVE
Nov 1, 2019, 00:00
10.1016/j.jval.2019.09.1040
https://www.valueinhealthjournal.com/article/S1098-3015(19)33418-7/fulltext
Title :
PDG26 COST-EFFECTIVENESS OF RANIBIZUMAB VERSUS VERTEPORFIN PHOTODYNAMIC THERAPY IN THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGICAL MYOPIA: FROM CHINESE SOCIETAL PERSPECTIVE
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)33418-7&doi=10.1016/j.jval.2019.09.1040
First page :
Section Title :
Open access? :
No
Section Order :
10914